YpsoMate with proprietary PLAJEX™ syringe for administration of the drug Hulio™ with the active ingredient adalimum.ab

First market entry of YpsoMate autoinjector from Ypsomed

Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Hulio® and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Hulio® is a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. The drug is used in the treatment of various chronic autoimmune diseases.

En savoir plus...

Ypsomed grows strongly with own products

Press Releases Ypsomed Group

Burgdorf – Ypsomed increased sales by CHF 45.3 million in the first half year of 2018/19. The operating result (EBIT) amounts to CHF 68.4 million. The result includes a CHF 49.8 million compensation from Insulet Corp. in terms of revenue and profit. The growth strategies with own products in expansion, innovation and production will be continued with determination. The mylife YpsoPump insulin pump is developing successfully above expectations.

En savoir plus...

Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring

Press Releases Ypsomed Group

Burgdorf and Eindhoven (NL) – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.

En savoir plus...

Ypsomed partners with JDRF

Ypsomed partners with JDRF to develop new open technologies for next-generation automated insulin delivery (AID) systems

Press Releases Ypsomed Group

Burgdorf/New York – JDRF, the leading global organization funding type 1 diabetes (T1D) research, has announced a partnership with Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, as part of JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative. The objective of the project is the development and regulatory approval of the next-generation mylife™ YpsoPump® insulin pump supporting incorporation into an automated insulin delivery (AID) system via open-protocol communication with third-party smartphone-based apps and/or other devices.

En savoir plus...

Topping-out ceremony at the new Ypsomed site in Schwerin
After completion of the building shell in the coming weeks, the interior work of the production plant will now begin.

Topping-out ceremony at the new Ypsomed site in Schwerin

Press Releases Ypsomed Group

Burgdorf/Schwerin - The topping-out ceremony for Ypsomed's new production plant took place on 28 June 2018. The Swiss medical technology company is building a new production plant in Schwerin's industrial park, creating around 150 new jobs in the region in the coming years. The new production plant will start operations in summer 2019.

En savoir plus...